Verona Pharma PLC (VRNA.OQ)

VRNA.OQ on NASDAQ Stock Exchange Global Market

18 Jan 2018
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Verona Pharma plc reports positive results from RPL554 dose-finding study
Tuesday, 15 Mar 2016 

Verona Pharma plc:Says positive headline data from a Phase IIa dose-finding clinical study using the Company's new proprietary nebulised formulation of RPL554.RPL554 is a novel inhaled PDE3/PDE4 inhibitor with both bronchodilator and anti-inflammatory properties in same molecule, currently in development as a nebulised treatment for acute exacerbations in chronic obstructive pulmonary disorder (COPD) patients in hospital or home-care setting.Says such patients typically require additional bronchodilation as well as anti-inflammatory treatment despite being on maximum doses of approved COPD medications (which often contain salbutamol).Says primary objective of study met.Nebulised RPL554 demonstrated a dose-dependent bronchodilator response in asthma patients; the response was highly statistically significant (p<0.0001) at all doses tested1.  Full Article

BRIEF-Verona Pharma announces positive top-line data from Phase 2A clinical trial in COPD with RPL554 dosed in addition to Tiotropium

* ANNOUNCES POSITIVE TOP-LINE DATA FROM PHASE 2A CLINICAL TRIAL IN COPD WITH RPL554 DOSED IN ADDITION TO TIOTROPIUM (SPIRIVA) Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)